Anti-Human Alpha Defensin-5 (HD5) – Purified in vivo GOLD™ Functional Grade
Anti-Human Alpha Defensin-5 (HD5) – Purified in vivo GOLD™ Functional Grade
Product No.: D400
Clone 8C8 Target HD5 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names DEFA5; DEF5; HD-5 Isotype Mouse IgG2b κ Applications ELISA , IHC FFPE , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Recombinant Human HD5 (aa 20-94). Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829963 Applications and Recommended Usage? Quality Tested by Leinco WB ELISA Additional Applications Reported In Literature ? IHC FFPE Dot Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 8C8 recognizes human alpha-defensin 5 (HD5). Background The colon lies adjacent to the small intestine and has heavy bacterial colonization from ingested food and water that is often contaminated with bacteria. Remarkably, the small intestine has a low microbial density. A special type of epithelial cell, called a Paneth cell, can be found clustered at the base of the tubular glands that lie between the villi of the inner surface of the small intestine. These cells secrete defensins which have been shown to have activity against both Gram-positive and Gram-negative microbes.3 Six human α-defensins, a subfamily of defensin peptides characterized by their cysteine spacing and disulfide connectivity2, have been identified. Human Paneth cells express α-defensin 5 (HD5) along with HD6. Paneth cells are most numerous in the ileum and have many features similar to those of myeloid cells. They are multifaceted cells with a large quantity of apically-located eosinophilic secretory granules containing lysozyme and other antimicrobial factors which are released upon bacterial stimulation.2 In addition, these cells express tumor necrosis factor alpha (TNF-a), CD1, and CD15.1 Paneth cells do not store defensins as fully processed or active peptides, rather they store them as inactive propeptides.2 They are released as mature peptides after trypsin digestion. Trypsin is also secreted from the Paneth cell granules. It has been reported that disrupted α-defensin processing in murine Paneth cells has initiated a vulnerability to enteric infection.2 HD5 expression levels have been found to be negatively correlated to intestinal infection. Additionally, studies have shown HD5 to be a strong antagonist towards human Papillomavirus infection. Furthermore, low expression of HD5 is thought to play a role in Crohn’s disease.3 Anti-Human Alpha Defensin-5 (HD5) Clone 8C8 has been shown to recognize the propeptide and the partially processed forms of HD5. However, clone 8C8 has been reported to scarcely recognize the mature peptide. There was no reported cross reactivity with HD6, lysozyme, or sPLA2. Antigen Distribution HD5 is highly expressed in the secretory granules of Paneth cells of the ileum. PubMed NCBI Gene Bank ID UniProt.org Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 8C8 is commonly used in in vivo mouse studies to detect and functionally investigate human alpha-defensin 5 (HD5), but only in experimental models where the human peptide is present, such as transgenic mice expressing human HD5; it does not cross-react with mouse defensins. Key applications include:
Importantly, clone 8C8 is not used in wild-type mice because it does not recognize murine defensin homologs. Its utility is therefore restricted to models with human HD5 transgene or xenograft systems. Additional notes:
In summary, clone 8C8’s in vivo applications in mice center on the functional and localization analysis of human HD5 in transgenic or xenograft contexts to model human intestinal immunity and related research questions. The most commonly used antibodies or proteins in the literature alongside 8C8 (which targets human alpha-defensin 5, HD5) are other anti-defensin and anti-L1 antibodies, particularly:
These are all monoclonal antibodies targeting the vaccinia virus L1 protein, often used in comparative or combinatorial studies with 8C8. This pattern is observed in immunological and virological research, where panels of related monoclonal antibodies (targeting the same or closely related proteins) are co-employed for specificity, epitope mapping, or functional studies. In studies focusing specifically on alpha-defensins (like HD5), other human alpha-defensins and their antibodies (such as those for HD6 and human neutrophil peptides 1–4) are also frequently used for comparative expression analysis, functional assays, and immunohistochemistry. Depending on experimental context, isotype controls and markers for immune cell subtypes or infection status may also be included, but these are standard in antibody-based assays. Summary of commonly co-used antibodies or proteins with 8C8:
No sources indicate routine co-use with unrelated proteins or antibodies outside these main classes when investigating HD5 or L1 in the referenced literature. The key findings from scientific literature regarding clone 8C8 are primarily related to its use as a monoclonal antibody. Clone 8C8 is used to detect specific proteins, particularly in assays such as immunophenotyping and flow cytometry. It is also cited as an antibody for Defensin alpha 5, validated for various laboratory techniques like IHC, WB, and ELISA. There is no specific mention of clone 8C8 in the broader context of clonal evolution or cellular biology beyond its application as an antibody. Summary of Key Findings:
Dosing regimens for clone 8C8 (anti-human alpha defensin 5, HD5) in mouse models are not standardized in the published literature; typical monoclonal antibody dosing in murine studies ranges from 5–300 μg per mouse per injection, with schedules varying from single administrations to repeated dosing (e.g., daily, every 3 days, or weekly). Specific protocols for clone 8C8 are not detailed in publicly available sources, so doses should be tailored to experimental aims and pilot safety/tolerability data. Essential supporting details:
Additional context:
Limitations:
Summary table: Antibody dosing guidance (generic, not 8C8-specific):
If you require precise dosing for clone 8C8 in a specific mouse model or disease context, pilot titration is recommended, starting in the 100–200 μg/mouse range and adjusted based on target engagement and safety. References & Citations1. Porter, EM. et al. (1997) Infect Immun. 65(6):2389-95. 2. Ghosh, D. et al. (2002) Nat Immunol. 3(6):583-90. 3. Wehkamp, J. et al. (2019) Proc Natl Acad Sci U S A. 116(9): 3746–3751. 4. Schwaderer, AL. et al. (2012) PLoS One. 7(2):e31712. 5. Hains, D. et al. (2016) US Patent Application Publication No. US 2016/0069905 A1 6. Shen, B. et al. (2005) J Clin Pathol. 58(7):687-94. 7. Ranki, A. et al. (2015) Clin Immunol. 158(2):212-20. 8. Hulscher, JB. et al. (2016) Pediatr Res. 80(2):306-10. Technical Protocols IHC FFPE   Certificate of Analysis |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
